Ocera Therapeutics, a biopharmaceutical company focused on treatments for gastrointestinal and liver diseases, said Feb. 20 it completed a late-stage financing round that raised $35.5 million.
Montagu Newhall Associates led the Series C round, which also involved InterWest Partners, AgeChem Venture Fund, Cross Creek, a subsidiary of Wasatch, FinTech and CDIB BioScience. Previous investors Domain Associates, Sofinnova Ventures and Thomas, McNerney & Partners also participated in the round.
To date, Ocera has raised a total of $62 million. In conjunction with the financing, Linda Grais of InterWest Partners was granted a seat on the Ocera board of directors.
, Heather Chambers